India Equity Research | Oil & Gas February 6, 2021 **Result Update**

Gujarat Gas

Refer to important disclosures at the end of this report

Strong show amid challenging conditions

- Gujarat Gas posted Q3FY21 EBITDA/PAT of Rs6.15bn/3.92bn, up 66%/100% yoy, down 16%/17% qoq and 40%/56% above estimates on a 6% volume beat and a 32% EBITDA/scm beat. Interest cost declined 28% qoq, with net debt down 19% to Rs7.0bn.
- Gas sales volumes grew 16% qoq (23% yoy) to 11.45mmscmd. Industrial PNG was up 17% qoq (29% yoy) to 9.2mmscmd, with Morbi up 20% to ~7.0mmscmd. On a yoy basis, CNG/Dom. PNG/Comm. PNG was up 2%/up 11%/down 18% to 1.5/0.6/0.1mmscmd.
- Net realization fell 3% qoq, while gas cost rose 9%, resulting in a gross margin decline of 24% qoq to Rs7.8/scm (an 18% beat though). Opex/scm fell 10% qoq to Rs1.9 (down 12% yoy and 12% below est.). EBITDA/scm came in at Rs5.8, down 28% qoq/up 35% yoy.
- We raise FY21/22/23E EPS by 14%/16%/13%, building in 5-7% higher volumes as well as EBITDA/scm each, based on strong run-rate and management guidance. We increase our DCF-based TP by 27% to Rs475 with a lower 10% WACC. Retain Buy with OW.

Highlights: GGL's margin beat was due to gas sourcing in advance at lower prices and GSPC group synergies. CNG/commercial PNG sales volume rose 20%/50% qoq while domestic PNG remained flat. Employee cost went up 1% yoy/down 6% qoq, while Other Expenditure rose 10%/8% to Rs1.58bn. Depreciation and tax rate were largely in line. GGL prepaid loans amounting to Rs9.88bn in 9MFY21. It commercialized 83 new CNG stations in 9M and incurred a total capex of Rs4.7bn.

Guidance: Current volumes are at ~11.5mmscmd, while FY21 exit is expected at 12mmscmd and FY22, on average, should be higher than the exit (12.5mmscmd our est.). Going ahead, GGL aims to clock at least 10% volume CAGR. Existing area ramp up as well new areas are adding to volumes. The company has started operations in all new GAs in terms of CNG stations, while PNG and industrial connectivity is underway. The NGT ban on South Gujarat cluster, PNGRB's restriction to GAIL in Dahej, etc. are other optional upsides. GGL's recent industrial PNG price hike of ~Rs4.96/scm is in response to spike in spot LNG prices. Morbi/non-Morbi pre-VAT prices are now at Rs33.0/34.8 per scm (6% additional VAT). Management expects Q4 EBITDA/scm to be in the Rs4.0-4.5 range at least, while FY22 guidance is ~Rs5.0. With propane prices moving up, GGL is in a comfortable position in terms of pricing. FY22/23 capex guidance stands at Rs8bn each. The implementation of GST in gas could entail ITC savings of Rs500mn annually to GGL (service tax paid being stranded now), while customers should benefit from ITC on the 6% VAT paid in gas purchases.

Valuation: Our Mar'23E DCF-based TP of Rs475 implies an 18.3x target PE multiple, which is reasonable with ~27% ROE/26% EPS CAGR for FY20-23E. **Key risks**: Adverse oil-gas prices, currency, regulations, competition and operational-project issues.

Please see our sector model portfolio (Emkay Alpha Portfolio): Oil & Gas (Page 7)

Financial Snapshot (Standalone)

(Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	77,544	103,003	97,338	133,884	152,896
EBITDA	10,039	16,343	20,017	24,412	27,484
EBITDA Margin (%)	12.9	15.9	20.6	18.2	18.0
APAT	3,580	9,034	12,141	15,532	17,862
EPS (Rs)	5.2	13.1	17.6	22.6	25.9
EPS (% chg)	13.1	152.4	34.4	27.9	15.0
ROE (%)	17.8	33.0	31.7	31.1	28.3
P/E (x)	73.1	29.0	21.5	16.8	14.6
EV/EBITDA (x)	28.0	16.8	13.4	10.7	9.2
P/BV (x)	12.0	7.9	6.0	4.6	3.7

Source: Company, Emkay Research



Your success is our success

СМР	Target Price
Rs 380 as of (February 6, 2021)	Rs 475 (▲) 12 months
Rating	Upside
BUY (∎)	25.0 %

Change in Estimates

enange in zeana			
EPS Chg FY21E/F	Y22E (%	b)	14/16
Target Price chang	e (%)		26.6
Target Period (Mor	nths)		12
Previous Reco			BUY
Emkay vs Consen	sus		
EPS E	Estimate	s	
	FY	21E	FY22E
Emkay		17.6	22.6
Consensus		15.3	18.8
Mean Consensus 7	TP (12M))	Rs 385
Stock Details			
Bloomberg Code		G	UJGA IN
Face Value (Rs)			2
Shares outstanding	g (mn)		688
52 Week H/L		4	12 / 191
M Cap (Rs bn/USD	bn)	26	62 / 3.59
Daily Avg Volume (nos.)	1	,048,321
Daily Avg Turnover	. (US\$ m	n)	5.1
Shareholding Patt	tern Dec	: '20	
Promoters			60.9%
FIIs			9.0%
DIIs			7.3%
Public and Others			22.8%
Price Performance			
(%) 1M	e 3M	6M	12M
.,	26	23	28
Absolute (2) Rel. to Nifty (7)	20	(8)	4
		(0)	
Relative price cha	irt		% г 30
1.0			الملكم
360 -		r	₩ - 22
320 -	MAC		- 14
280 -	V V I	. N	6
240		V.A.	∛ 2
200 Feb-20 Apr-20 Jun-20 A	Aug-20 Oct-	-20 Dec-2	
Gujarat Gas (LHS	-		Nifty (RHS)
Source: Bloomberg			
This report is solely pro following person(s) are production of the recom	responsib	e for the	
Sabri Hazarika			
sabri.hazarika@em	kayglob	al.com	
+91 22 6612 1282			
Tanay Gabhawala			
tanay.gabhawala@	emkayg	obal.c	om

+91 22 6612 1336

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMIKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Exhibit 1: Actual vs. Estimates (Q3FY21)

Po mn	Actual	Estimates	Consensus	Va	ariation	Commont
Rs mn	Actual	(Emkay)	Estimates (Bloomberg)	Emkay	Consensus	Comment
Total Revenue	28,294	27,324	26,700	4%	6%	Higher-than-expected volumes
EBITDA	6,148	4,398	4,400	40%	40%	Better gross margin, lower opex
EBITDA Margin (%)	22%	16%	16%	563bps	525bps	
Adjusted Net Profit	3,922	2,518	2,600	56%	51%	Lower interest cost, higher Other Income
Source: Company, Emkay Resear	ch		•			

Exhibit 2: Quarterly summary

Rs.mn	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	YoY	QoQ	9MFY20	9MFY21	YoY
Total Revenue	25,062	26,666	10,829	25,130	28,294	13%	13%	76,337	64,253	-16%
Dec./(Inc.) in Stock In Trade	-0	1	5	-0	-6			0	-1	
Raw Material Cost	19,482	20,263	7,292	15,876	20,131	3%	27%	58,553	43,298	-26%
Total COGS	19,482	20,264	7,297	15,876	20,124	3%	27%	58,554	43,297	-26%
Adjusted Gross Profit	5,580	6,402	3,532	9,255	8,170	46%	-12%	17,784	20,956	18%
Employee Cost	438	406	426	468	442	1%	-6%	1,348	1,336	-1%
Other Expenses	1,437	1,730	1,249	1,456	1,580	10%	8%	4,360	4,284	-2%
OPEX	1,875	2,135	1,675	1,924	2,022	8%	5%	5,707	5,621	-2%
Adjusted EBITDA	3,705	4,267	1,857	7,330	6,148	66%	-16%	12,076	15,336	27%
Depreciation	795	805	823	856	862	8%	1%	2,375	2,540	7%
EBIT	2,911	3,462	1,035	6,474	5,287	82%	-18%	9,701	12,796	32%
Interest Cost	465	420	401	339	243	-48%	-28%	1,502	983	-35%
Other Income	186	189	149	208	196	5%	-6%	648	552	-15%
PBT Before Exceptional Items	2,632	3,231	783	6,343	5,239	99%	-17%	8,847	12,365	40%
Exceptional Items	-	-	-	-	-			-	-	
PBT	2,632	3,231	783	6,343	5,239	99%	-17%	8,847	12,365	40%
Current Tax	656	753	192	1,545	1,385	111%	-10%	2,184	3,123	43%
Deferred Tax	11	19	4	50	-68			-2,812	-13	
Total Tax	667	772	196	1,595	1,318	98%	-17%	-627	3,109	
Reported PAT	1,965	2,459	587	4,748	3,922	100%	-17%	9,475	9,256	-2%
Reported EPS (Rs.)	2.9	3.6	0.9	6.9	5.7	100%	-17%	13.8	13.4	-2%
Adjusted PAT	1,965	2,459	587	4,748	3,922	100%	-17%	6,258	9,256	48%
Adjusted EPS (Rs.)	2.9	3.6	0.9	6.9	5.7	100%	-17%	9.1	13.4	48%
Shares O/S (mn)	688	688	688	688	688	0%	0%	688	688	0%
EBITDA Margin	15%	16%	17%	29%	22%			16%	24%	
NPM	8%	9%	5%	19%	14%			12%	14%	
Effective Tax Rate	25%	24%	25%	25%	25%			-7%	25%	
Sales Volume (mmscmd)	9.3	9.9	4.1	9.8	11.4	23%	16%	9.3	8.5	-8%
Industrial PNG	7.1	7.7	2.9	7.9	9.2	29%	17%	7.1	6.6	-7%
Commercial PNG	0.1	0.1	0.0	0.1	0.1	-18%	50%	0.1	0.1	-40%
Domestic PNG	0.6	0.7	0.6	0.6	0.6	11%	0%	0.5	0.6	15%
CNG	1.5	1.5	0.7	1.3	1.5	2%	20%	1.5	1.2	-21%
Average Realization (Rs./scm)	29.2	29.5	28.7	27.7	26.9	-8%	-3%	29.9	27.5	-8%
Gross Margin (Rs./scm)	6.5	7.1	9.4	10.2	7.8	19%	-24%	7.0	9.0	29%
Opex (Rs./scm)	2.2	2.4	4.4	2.1	1.9	-12%	-10%	2.2	2.4	7%
EBITDA/scm (Rs.)	4.3	4.7	4.9	8.1	5.8	35%	-28%	4.7	6.6	39%

Source: Company, Emkay Research

Exhibit 3: Changes in assumptions

Rs mn		FY21E			FY22E			FY23E	
K3 IIII	Previous	Revised	Variance	Previous	Revised	Variance	Previous	Revised	Variance
EBITDA/scm (Rs.)	5.6	5.9	5%	5.1	5.4	6%	5.2	5.4	5%
Volumes (mmscmd)	8.8	9.2	5%	11.7	12.5	7%	13.1	14.0	7%
Growth	-7%	-2%	504bps	33%	35%	186bps	12%	12%	0bps

Source: Company, Emkay Research

Exhibit 4: Changes in estimates

Rs mn		FY21E			FY22E			FY23E	
KS IIII	Previous	Revised	Variance	Previous	Revised	Variance	Previous	Revised	Variance
Revenue	89,717	97,338	8%	121,691	133,884	10%	138,967	152,896	10%
EBITDA	18,044	20,017	11%	21,512	24,412	13%	24,558	27,484	12%
EBITDA Margins	20%	21%	45bps	18%	18%	56bps	18%	18%	30bps
PAT	10,613	12,141	14%	13,399	15,532	16%	15,789	17,862	13%
EPS (Rs)	15.4	17.6	14%	19.5	22.6	16%	22.9	25.9	13%

Source: Company, Emkay Research

Exhibit 5: DCF valuation			
DCF assumptions		Mar'23E (Rs mn)	
Risk Free Rate	6.0%	NPV Of FCF	117,014
Risk Premium	5.5%	Terminal Value	543,472
Beta	0.8	PV Of TV	209,935
Cost Of Equity	10.1%	Total Value	326,949
Cost Of Debt	9.0%	Less: Net Debt (Y/E)	(72)
Post Tax Cost Of Debt	6.8%	Equity Value	327,021
Average Debt:Equity Ratio	30.0%	No. Of Shares O/S (mn)	688
WACC	9.3%	Target Price (Rs.)	475
Terminal Growth Rate	2.0%		

Source: Company, Emkay Research

Exhibit 6: PE-based valuation

Rs.	FY18	FY19	FY20	FY21E	FY22E	FY23E
Adjusted EPS	4.6	5.2	13.1	17.6	22.6	25.9
Target Multiple (x)						18.3
DCF Target Price						475

Source: Company, Emkay Research

Key Financials (Standalone)

Income Statement

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Revenue	77,544	103,003	97,338	133,884	152,896
Expenditure	67,505	86,661	77,321	109,471	125,413
EBITDA	10,039	16,343	20,017	24,412	27,484
Depreciation	2,880	3,180	3,449	3,930	4,391
EBIT	7,159	13,163	16,569	20,482	23,093
Other Income	1,113	837	814	913	1,053
Interest expenses	1,962	1,922	1,151	630	266
РВТ	6,310	12,078	16,231	20,765	23,880
Тах	1,768	145	4,090	5,233	6,018
Extraordinary Items	(962)	(2,899)	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	4,170	11,933	12,141	15,532	17,862
Adjusted PAT	3,580	9,034	12,141	15,532	17,862

Balance Sheet

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
Equity share capital	1,377	1,377	1,377	1,377	1,377
Reserves & surplus	20,463	31,529	42,214	54,950	68,525
Net worth	21,840	32,906	43,590	56,327	69,902
Minority Interest	0	0	0	0	0
Loan Funds	22,131	20,554	16,054	11,054	6,054
Net deferred tax liability	10,816	8,005	7,992	7,979	7,966
Total Liabilities	54,787	61,465	67,636	75,359	83,921
Net block	55,193	58,086	62,952	68,771	75,227
Investment	190	200	200	200	200
Current Assets	11,004	14,992	16,851	21,019	24,663
Cash & bank balance	3,092	6,919	9,008	11,125	13,662
Other Current Assets	791	817	841	866	892
Current liabilities & Provision	16,488	17,508	17,492	19,244	20,321
Net current assets	(5,484)	(2,516)	(642)	1,775	4,343
Misc. exp	0	0	0	0	0
Total Assets	54,787	61,465	67,636	75,359	83,921

Cash Flow

Y/E Mar (Rs mn)	FY19	FY20	FY21E	FY22E	FY23E
PBT (Ex-Other income) (NI+Dep)	5,197	11,241	15,418	19,852	22,827
Other Non-Cash items	(107)	266	0	0	0
Chg in working cap	1,161	(1,952)	202	(313)	(44)
Operating Cashflow	9,644	14,221	16,062	18,797	21,351
Capital expenditure	(4,521)	(6,880)	(7,745)	(9,237)	(10,385)
Free Cash Flow	5,123	7,341	8,316	9,560	10,966
Investments	(16)	(10)	0	0	0
Other Investing Cash Flow	(2,700)	1,384	67	69	72
Investing Cashflow	(6,124)	(4,668)	(6,864)	(8,255)	(9,261)
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	(1,151)	(1,578)	(4,500)	(5,000)	(5,000)
Dividend paid (incl tax)	(408)	(837)	(1,457)	(2,796)	(4,287)
Other Financing Cash Flow	1,730	(1,389)	0	0	0
Financing Cashflow	(1,791)	(5,725)	(7,108)	(8,426)	(9,553)
Net chg in cash	1,729	3,827	2,090	2,117	2,537
Opening cash position	1,363	3,092	6,919	9,008	11,125
Closing cash position	3,092	6,919	9,008	11,125	13,662

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

12.9 9.2 28.0 5.9 15.5 17.8 15.5 FY19 5.2 9.4 31.7 1.0 FY19	15.9 12.8 1.2 11.6 24.1 33.0 27.6 FY20 13.1 17.7 47.8 1.3	20.6 17.0 25.2 12.5 26.9 31.7 32.5 FY21E 17.6 22.6 63.3 1.8	18.2 15.3 25.2 11.6 29.9 31.1 36.3 FY22E 22.6 28.3 81.8	18.0 15.1 25.2 11.7 30.3 28.3 36.9 FY23E 25.9 32.3
28.0 5.9 15.5 17.8 15.5 FY19 5.2 9.4 31.7 1.0 FY19	1.2 11.6 24.1 33.0 27.6 FY20 13.1 17.7 47.8 1.3	25.2 12.5 26.9 31.7 32.5 FY21E 17.6 22.6 63.3	25.2 11.6 29.9 31.1 36.3 FY22E 22.6 28.3	25.2 11.7 30.3 28.3 36.9 FY23E 25.9
5.9 15.5 17.8 15.5 FY19 5.2 9.4 31.7 1.0 FY19	11.6 24.1 33.0 27.6 FY20 13.1 17.7 47.8 1.3	12.5 26.9 31.7 32.5 FY21E 17.6 22.6 63.3	11.6 29.9 31.1 36.3 FY22E 22.6 28.3	11.7 30.3 28.3 36.9 FY23E 25.9
15.5 17.8 15.5 FY19 5.2 9.4 31.7 1.0 FY19	24.1 33.0 27.6 FY20 13.1 17.7 47.8 1.3	26.9 31.7 32.5 FY21E 17.6 22.6 63.3	29.9 31.1 36.3 FY22E 22.6 28.3	30.3 28.3 36.9 FY23E 25.9
17.8 15.5 FY19 5.2 9.4 31.7 1.0 FY19	33.0 27.6 FY20 13.1 17.7 47.8 1.3	31.7 32.5 FY21E 17.6 22.6 63.3	31.1 36.3 FY22E 22.6 28.3	28.3 36.9 FY23E 25.9
15.5 FY19 5.2 9.4 31.7 1.0 FY19	27.6 FY20 13.1 17.7 47.8 1.3	32.5 FY21E 17.6 22.6 63.3	36.3 FY22E 22.6 28.3	36.9 FY23E 25.9
FY19 5.2 9.4 31.7 1.0 FY19	FY20 13.1 17.7 47.8 1.3	FY21E 17.6 22.6 63.3	FY22E 22.6 28.3	FY23E 25.9
5.2 9.4 31.7 1.0 FY19	13.1 17.7 47.8 1.3	17.6 22.6 63.3	22.6 28.3	25.9
5.2 9.4 31.7 1.0 FY19	13.1 17.7 47.8 1.3	17.6 22.6 63.3	22.6 28.3	25.9
31.7 1.0 FY19	47.8 1.3	63.3		32.3
31.7 1.0 FY19	1.3	63.3	81.8	
1.0 FY19		1.8		101.5
			3.4	5.2
	E1/00	EVOLE	EVOOE	EVOOF
	FY20	FY21E	FY22E	FY23E
73.1	29.0	21.5	16.8	
40.5	21.4	16.8	13.4	11.8
				3.7
				1.7
				9.2
0.3	0.3	0.5	0.9	1.4
FY19	FY20	FY21E	FY22E	FY23E
0.9	0.4	0.2	0.0	(0.1)
1.9	0.8	0.4	0.0	(0.3)
8.2	4.3	4.3	4.3	4.3
FY19	FY20	FY21E	FY22E	FY23E
25.6	32.8	(5.5)	37.5	14.2
10.2	62.8	22.5	22.0	12.6
12.0	83.9	25.9	23.6	12.7
43.1	186.1	1.7	27.9	15.0
O3EV20	04EV20	01EV21	O2EV21	Q3FY21
				28,294
				6,148
		-	-	21.7
				3,922
				5.7
	0.0	010	0.0	
Dec-19	Mar-20	Jun-20	Sep-20	Dec-20
60.9	60.9	60.9	60.9	60.9
11.1	9.8	9.2	9.1	9.0
11.1				0.0
6.3	7.0	7.4	7.3	7.3
	0.9 1.9 8.2 FY19 25.6 10.2 12.0 43.1 Q3FY20 25,062 3,705 14.8 1,965 2.9	3.6 2.7 28.0 16.8 0.3 0.3 FY19 FY20 0.9 0.4 1.9 0.8 8.2 4.3 FY19 FY20 25.6 32.8 10.2 62.8 12.0 83.9 43.1 186.1 Q3FY20 Q4FY20 25,062 26,666 3,705 4,267 14.8 16.0 1,965 2,459 2.9 3.6	3.6 2.7 2.8 28.0 16.8 13.4 0.3 0.3 0.5 FY19 FY20 FY19 FY20 FY21E 0.9 0.4 0.2 1.9 0.8 0.4 8.2 4.3 4.3 FY19 FY20 FY19 FY20 FY21E 25.6 32.8 (5.5) 10.2 62.8 22.5 12.0 83.9 25.9 43.1 186.1 1.7 Q3FY20 Q4FY20 Q1FY21 25,062 26,666 10,829 3,705 4,267 1,857 14.8 16.0 17.2 1,965 2,459 587 2.9 3.6 0.9	3.6 2.7 2.8 2.0 28.0 16.8 13.4 10.7 0.3 0.3 0.5 0.9 FY19 FY20 FY21E FY22E 0.9 0.4 0.2 0.0 1.9 0.8 0.4 0.0 8.2 4.3 4.3 4.3 FY19 FY20 FY21E FY22E 25.6 32.8 (5.5) 37.5 10.2 62.8 22.5 22.0 12.0 83.9 25.9 23.6 43.1 186.1 1.7 27.9 Q3FY20 Q4FY20 Q1FY21 Q2FY21 25,062 26,666 10,829 25,130 3,705 4,267 1,857 7,330 14.8 16.0 17.2 29.2 1,965 2,459 587 4,748 2.9 3.6 0.9 6.9

Source: Capitaline

RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
27-Nov-20	349	375	12m	Buy	Sabri Hazarika
6-Nov-20	313	375	12m	Buy	Sabri Hazarika
28-Sep-20	302	365	12m	Buy	Sabri Hazarika
5-Aug-20	308	365	12m	Buy	Sabri Hazarika
6-Jun-20	286	260	12m	Hold	Sabri Hazarika
6-May-20	235	280	12m	Hold	Sabri Hazarika
6-Feb-20	302	280	12m	Hold	Sabri Hazarika
24-Jan-20	294	235	12m	Buy	Sabri Hazarika
4-Dec-19	217	235	12m	Buy	Sabri Hazarika
6-Nov-19	196	235	12m	Buy	Sabri Hazarika
25-Oct-19	178	225	12m	Buy	Sabri Hazarika
23-Sep-19	182	225	12m	Buy	Sabri Hazarika
30-Jul-19	164	200	12m	Buy	Sabri Hazarika
1-Jul-19	172	190	12m	Buy	Sabri Hazarika
10-Jun-19	186	190	12m	Buy	Sabri Hazarika
6-May-19	160	190	12m	Buy	Sabri Hazarika
1-Apr-19	145	190	12m	Buy	Sabri Hazarika
8-Mar-19	136	170	12m	Buy	Sabri Hazarika
8-Feb-19	124	170	12m	Buy	Sabri Hazarika
28-Jan-19	127	173	12m	Buy	Sabri Hazarika
31-Dec-18	134	173	12m	Buy	Sabri Hazarika
11-Dec-18	125	173	12m	Buy	Sabri Hazarika
5-Nov-18	125	173	12m	Buy	Sabri Hazarika
4-Sep-18	149	186	12m	Buy	Sabri Hazarika
13-Jul-18	152	186	12m	Buy	Sabri Hazarika
8-Jun-18	166	186	12m	Buy	Sabri Hazarika
14-May-18	177	186	12m	Buy	Sabri Hazarika

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

Source: Company, Emkay Research



Analyst: Sabri Hazarika

Contact Details

sabri.hazarika@emkayglobal.com +91 22 6612 1282

Sector

Oil & Gas

Analyst bio

Sabri Hazarika holds an MBA and comes with 11 years of research experience. His team currently covers 12 stocks in the Indian Oil & Gas space.

Emkay Alpha Portfolio – Oil & Gas

EAP sector portfolio

Company Name	BSE200 Weight	EAP Weight	OW/UW (%)	OW/UW (bps)	EAP Weight (Normalised)
Oil & Gas	9.81	9.80	0%	-1	100.00
BPCL	0.41	0.45	10%	4	4.55
GAIL	0.28	0.26	-7%	-2	2.70
Gujarat Gas	0.08	0.09	18%	1	0.95
Gujarat State Petronet	0.07	0.07	1%	0	0.73
Gulf Oil Lubricants	0.00	0.05	NA	5	0.51
HPCL	0.21	0.23	10%	2	2.32
Indian Oil	0.32	0.29	-7%	-2	3.00
Indraprastha Gas	0.23	0.16	-30%	-7	1.63
Petronet LNG	0.23	0.24	4%	1	2.40
Oil India	0.05	0.03	-38%	-2	0.32
ONGC	0.43	0.47	9%	4	4.80
Reliance Industries	7.51	7.46	-1%	-5	76.00
Cash	0.00	0.01	NA	1	0.08

Source: Emkay Research

* Not under coverage: Equal Weight

High Conviction/Strong Over Weight

Sector portfolio NAV

Base				_	Latest
1-Apr-19	6-Feb-20	6-Aug-20	5-Nov-20	5-Jan-21	4-Feb-21
100.0	98.6	128.0	117.6	123.0	121.9
100.0	99.8	127.1	116.7	122.2	121.2
	1-Apr-19 100.0	1-Apr-19 6-Feb-20 100.0 98.6	1-Apr-19 6-Feb-20 6-Aug-20 100.0 98.6 128.0	1-Apr-19 6-Feb-20 6-Aug-20 5-Nov-20 100.0 98.6 128.0 117.6	1-Apr-19 6-Feb-20 6-Aug-20 5-Nov-20 5-Jan-21 100.0 98.6 128.0 117.6 123.0


*Performance measurement base date 1st April 2019 Source: Emkay Research

Price Performance (%)

1m	3m	6m	12m
-0.9%	3.7%	-4.7%	23.6%
-0.8%	3.8%	-4.7%	21.4%
	-0.9%	-0.9% 3.7%	-0.9% 3.7% -4.7%

Source: Emkay Research





Source: Emkay Research

Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID

"Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha Portfolios Report and is updated on regular intervals"

Emkay Rating Distribution

12-18 months.

Completed Date: 07 Feb 2021 01:13:11 (SGT) Dissemination Date: 07 Feb 2021 01:14:11 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or has associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of February 6, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of February 6, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the February 6, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the February 6, 2021

RESTRICTIONS ON [DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com